VERACITY Advanced - non-invasive prenatal testing (NIPT)

VERACITY Advanced is a next-generation non-invasive prenatal test (NIPT) that accurately measures cell-free foetal DNA present in the mother’s blood. The test is safe and does not involve invasive procedures, so there is no risk to the pregnant woman or the foetus.

The VERACITY Advanced test involves a detailed analysis of cell-free foetal DNA present in the pregnant woman’s blood, aimed at detecting any trisomies, aneuploidies and microdeletions of the foetus at an early stage of pregnancy.

VERACITY Advanced is based on proprietary technology, specifically designed to avoid genomic regions with complex architecture that affect the performance of the test. This eliminates problems common to other NIPTs, while increasing the precision and accuracy of the VERACITY Advanced test. In addition, the read depth of the test provides information on the number of times a given nucleotide in the genome is read during the analysis.

The VERACITY Advanced test captures DNA fragments from target regions of the selected chromosomes. With VERACITY, it is possible to analyse such target regions at a very high read-depth, which improves the statistical accuracy of the analysis and increases the sensitivity and specificity of the test. Meanwhile, the proprietary bioinformatics software accurately calculates the foetal fraction. Accurate measurement of the foetal fraction increases the reliability and credibility of the VERACITY Advanced test.

The effectiveness of the innovative VERACITY AdvancedY test has been confirmed in singleton and twin pregnancies, as well as those resulting from in vitro fertilisation.

Scope of the test 

The VERACITY Advanced test offers the most comprehensive testing scope available on the market. It allows for the detection of the following abnormalities:  

Trisomies (autosomal aneuploidies – abnormalities in the number of autosomal chromosomes) 

• Down syndrome (trisomy 21) 
• Edwards syndrome (trisomy 18) 
• Patau syndrome (trisomy 13) 

Sex chromosome aneuploidies (abnormalities in the number of X or Y chromosomes) 

• Turner syndrome (monosomy X) 
• Triple X syndrome (trisomy X) 
• Klinefelter syndrome (XXY) 
• Jacobs syndrome (XYY) 
• XXYY syndrome 

Microdeletions (changes within the chromosome structure) 

• DiGeorge syndrome (22q11.2) 
• Smith-Magenis syndrome (17p11.2) 
• Wolf-Hirschhorn syndrome (4p16.3) 
• 1p36 deletion syndrome 
• Prader-Willi and Angelman syndromes (15q11.2-q13)
• Cri du Chat syndrome (5p deletion)

Worth knowing:
Microdeletions are small losses of DNA that occur with the same frequency in women of all ages. Their size is only about 2.5 Mb, but they can cause serious diseases. The VERAgene test detects abnormalities as small as 0.5 Mb, making it the most reliable test available on the market.
An example of such a condition is the 22q11.2 deletion, known as DiGeorge syndrome. This genetic defect is the second most common after Down syndrome and occurs on average in 1 out of every 1,000 live births. Early diagnosis is crucial for selecting effective therapy.

The test also detects the presence of the Y chromosome, which makes it possible to determine the baby’s sex (at the parents’ request).  

Why VERACITY Advanced?  

The VERACITY Advanced test is one of the most accurate tests for detecting Down syndrome, Edwards syndrome, and Patau syndrome. It detects more developmental abnormalities than traditional first-trimester screening tests and can be performed as early as the 9th week of pregnancy (earlier than the PAPP-A test and first-trimester ultrasound).  

The VERACITY Advanced test is a medical device. For your safety, use it in accordance with the instructions or label. If in doubt, consult a specialist. The VERACITY and VERAgene prenatal tests are manufactured by Medicover Genetics.

For whom is the VERACITY Advanced test intended?

The test is intended for women:

• of all ages;
• from the 9th week of pregnancy;
• having singleton and twin pregnancies as well as suffering from the vanishing twin syndrome;
• after in vitro fertilisation (excluding IVF with a donor egg).

Contraindications for the test include:

• a higher-order multiple pregnancy;
• the risk of a specific genetic defect shown by the PAPP-A test being greater than 1:100 (in such a case, it is necessary to undergo an invasive test, e.g. amniocentesis);
• identified mosaicism of the placenta, mother or foetus;
• organ or bone marrow transplantation in the mother;
• the mother undergoing a blood transfusion within the past 1-2 months;
• diagnosis of a balanced translocation in either parent;
• the mother suffering from malignant tumour (currently or in the past).

What are the advantages of undergoing the VERACITY Advanced test?
If you decide to undergo the VERACITY Advanced test at Medicover, our specialists will provide you with comprehensive medical care. As part of the service, we guarantee a free consultation with a clinical geneticist and a psychologist for any patient who receives a high-risk result.

Preparation for the test

The test does not require any preparation, including fasting.

 

Please remember to bring your ID card or any other identity document to the appointment.

You can undergo VeraCity within 3 months of its purchase (counting from the date indicated in the order confirmation).

To make an appointment for the test, please call our hotline on +48 500 900 505. The appointment will take place at the blood drawing point. A referral can be completed on site with the assistance of the medical staff. A referral from a doctor is not required.

Result

The test result will be available in 7-10 working days.

If you decide to undergo the VERACITY test at Medicover, our specialists will provide you with comprehensive medical care. As part of the service, we guarantee a free consultation with a clinical geneticist and a psychologist for any patient who receives a high-risk result.

• The result of the test will be sent to the patient by email to the address indicated in the referral.
• In the case of a result showing a high risk of a disease entity, the patient will be contacted by a gynaecologist.